SenzaGen signs distribution agreement with GenEvolutioN in France
SenzaGen has signed a three-year distribution agreement with the French contract research laboratory GenEvolutioN. With this agreement SenzaGen further broadens its licensing and distribution network in Europe with another strategically important partner for toxicological in vitro studies.
GenEvolutioN is an innovative and privately owned GLP-certified contract research organization (CRO) with many years of in vitro toxicology expertise and specialist knowledge in cell-based methods. In a short time, the company has established itself as a supplier of high-tech and advanced testing services with customers in the pharmaceutical, cosmetics and chemical industries in seven countries.
“GenEvolutioN possesses an impressive level of expertise in the field of alternative testing without animal models and gives us access to world-leading customers within our prioritized industries. Collaboration with strong partners is part of our commercial strategy and together with GenEvolutioN, we continue to establish the GARD™ technology in the important European market," says Axel Sjöblad, CEO of SenzaGen.
“GenEvolutioN stands for quality and scientific excellence. We offer only the best services and tools in line with the evolution of biological and technological progress; therefore, we are very careful with partnerships and the services we add to our portfolio. Our customers are increasingly demanding sensitization testing and it is gratifying that we now can offer them the high-performance GARD™ technology,” says Francis Finot, founder and owner of GenEvolutioN.
The agreement gives GenEvolutioN the right to market and sell SenzaGen's GARD™ tests to customers looking for advanced technology providing reliable results. Through its accuracy and reliability, GARD™ improves the quality of customer's decision-making and contributes to increased product safety in people's everyday lives.
The agreement between SenzaGen and GenEvolutioN runs for three years with an option to extend for additional years.
For more information, please contact:
Axel Sjöblad, CEO, SenzaGen AB
Email: axel.sjoblad@senzagen.com | Mobil: +46 705-35 93 51
Francis Finot, Co-Founder, GenEvolutioN SAS
Email: francis.finot@genevolution.fr | Mobil: +33 (0)- 65 75 94 78
About GARD™
GARD™ consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence. By analyzing hundreds of markers, GARD™ generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today’s standard method – tests on animals – which only achieves 70-75 percent accuracy. The product portfolio consists of tests for skin and respiratory allergy: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.
About SenzaGen AB (publ)
SenzaGen’s technology enables replacement of animal experiments with genetic testing in test tubes for determining the allergenicity of the chemicals we come into contact with in our daily lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct in Sweden and the US, and through partners in several other countries. Over the next few years the company will grow geographically, make alliances with additional distribution and license partners, and launch new unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the US. For more information, please visit www.senzagen.com.
SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser.
About GenEvolutioN
GenEvolutioN established in 2017, is an expert spin off, dedicated to in vitro genetic toxicology and toxicology expertise using new Human cell models. GenEvolutioN is in line with the evolution of biological and technological progress. Please visit www.genevolution.fr.
